Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT04065633
Previous Study | Return to List | Next Study

Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04065633
Recruitment Status : Completed
First Posted : August 22, 2019
Last Update Posted : January 7, 2020
Sponsor:
Information provided by (Responsible Party):
Pfizer

Brief Summary:

Part A

  • To measure and compare the amount of study drug in the blood after a single 200 mg dose of study drug given as the commercial tablet formulation and the Phase 3 tablet formulation under fasting conditions
  • To measure and compare the amount of study drug in the blood after a single 200 mg dose given as the variant Phase 3 tablet formulation and the Phase 3 tablet formulation under fasting conditions
  • To estimate the effect of food on the amount of study drug in the blood after a single 200 mg dose of the commercial formulation

Part B

• To measure and compare the amount of study drug in the blood after a single 200 mg dose given as the commercial tablet formulation and the Phase 3 tablet formulation under fasting conditions

Parts A & B

  • To collect samples for genotyping (CYP2C19 and CYP2C9 - enzymes that metabolize [break down] certain medications)

    o Genotyping is the collection of a small sample of blood that contains your genes

  • To evaluate the safety and tolerability of the study drug after single 200 mg doses of the three different formulations given to healthy participants
  • To measure the amount of study drug in the blood after single doses of the different formulations
  • To collect exploratory samples for biobanking o Biobanking is the collection and storage of blood samples for possible future testing

Condition or disease Intervention/treatment Phase
Dermatitis, Atopic Drug: P3-Fast Drug: Comm-Fast Drug: Vari-Fast Drug: Comm-Fed Phase 1

Detailed Description:

The purpose of this study in healthy participants is to estimate the bioavailability (BA) of the commercial formulation of PF-04965842 and a variant formulation with slower dissolution relative to the Phase 3 formulation, to demonstrate the bioequivalence (BE) of the commercial formulation relative to the Phase 3 formulation, and to estimate the effect of food on the BA of the commercial formulation. This study consists of 2 parts: Part A is to estimate the relative BA (rBA) of single 200 mg doses of the commercial tablet formulation of PF-04965842 and a variant formulation of slower dissolution rate compared to the Phase 3 tablet formulation. The effect of food on the BA of the commercial tablet formulation will also be evaluated. Part B is to establish BE between the Phase 3 and commercial formulations. The study will follow a staged approach as the sample size for BE cannot be determined with currently available information.

Therefore, it is proposed to assess the maximum observed concentration (Cmax) and area under the curve (AUC) ratios between the Phase 3 and commercial formulations as well as the within-participant variability of Cmax and AUC values determined in Part A. Based on the results from Part A, the sample size of Part B will be determined and the decision to proceed to Part B will be made.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 46 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: This is a Phase 1 randomized, open label, single-dose, crossover study in healthy participants to estimate the rBA of the commercial formulation of PF-04965842 (Test formulation 1) and the variant formulation with slower dissolution (Test formulation 2) compared to the Phase 3 formulation (Reference formulation), to demonstrate the BE of the commercial formulation relative to the Phase 3 formulation, and to estimate the effect of food on the rBA of the commercial formulation after a single 200 mg oral dose.
Masking: None (Open Label)
Primary Purpose: Other
Official Title: A PHASE 1, OPEN LABEL, SINGLE-DOSE, CROSSOVER STUDY TO EVALUATE THE BIOEQUIVALENCE OF A COMMERCIAL TABLET FORMULATION OF PF-04965842 RELATIVE TO THE PHASE III TABLET FORMULATION UNDER FASTING CONDITIONS AND THE EFFECT OF FOOD ON THE RELATIVE BIOAVAILABILITY OF THE COMMERCIAL TABLET FORMULATION IN HEALTHY PARTICIPANTS
Actual Study Start Date : July 18, 2019
Actual Primary Completion Date : December 14, 2019
Actual Study Completion Date : December 14, 2019

Arm Intervention/treatment
Experimental: Part A sequence 1 Drug: P3-Fast
200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions

Drug: Comm-Fast
200 mg PF-04965842 commercial tablet formulation under fasted conditions

Drug: Vari-Fast
200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions

Drug: Comm-Fed
200 mg PF-04965842 commercial tablet formulation under fed conditions

Experimental: Part A sequence 2 Drug: P3-Fast
200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions

Drug: Comm-Fast
200 mg PF-04965842 commercial tablet formulation under fasted conditions

Drug: Vari-Fast
200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions

Drug: Comm-Fed
200 mg PF-04965842 commercial tablet formulation under fed conditions

Experimental: Part B sequence 1 Drug: P3-Fast
200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions

Drug: Comm-Fast
200 mg PF-04965842 commercial tablet formulation under fasted conditions

Experimental: Part B sequence 2 Drug: P3-Fast
200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions

Drug: Comm-Fast
200 mg PF-04965842 commercial tablet formulation under fasted conditions




Primary Outcome Measures :
  1. Plasma PF-04965842 PK parameters [ Time Frame: hour 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose ]
    AUCinf

  2. Plasma PF-04965842 PK parameters [ Time Frame: hour 0, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48 hours post-dose ]
    Cmax


Secondary Outcome Measures :
  1. number of subjects with treatment-emergent adverse event [ Time Frame: baseline until Period 4 study day 35 ]
  2. number of subjects with significant change from baseline in Supine Blood pressure, pulse rate and oral temperature [ Time Frame: baseline until Period 4 study day 3 ]
    The actual and the change from baseline values will be summarized by treatment. These data will be listed and out of range values will be summarized

  3. number of subjects with significant Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR [ Time Frame: baseline until Period 4 study day 3 ]
    Changes from baseline for the ECG parameters QT interval, heart rate, QTc interval, PR interval, and QRS complex will be summarized by treatment and time. The number (%) of participants with maximum postdose QTc values and maximum increases from baseline in the following categories will be tabulated by treatment



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 55 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Body mass index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lb)

Exclusion Criteria:

  • Any condition possibly affecting drug absorption (eg, gastrectomy).

    • History of human immunodeficiency virus (HIV) infection, hepatitis B, or hepatitis
    • Evidence or history of clinically significant dermatological condition (eg, atopic dermatitis or psoriasis) .History of tuberculosis (TB) (active or latent) or inadequately treated TB infection.
    • History of chronic infections, history of recurrent infections, history of latent infections, .History of disseminated herpes zoster, or disseminated herpes simplex, or recurrent localized dermatomal herpes zoster.
    • history of malignancies with the exception of adequately treated or excised non-metastatic basal cell or squamous cell cancer of the skin, or cervical carcinoma in situ

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04065633


Locations
Layout table for location information
United States, Connecticut
New Haven Clinical Research Unit
New Haven, Connecticut, United States, 06511
Sponsors and Collaborators
Pfizer
Investigators
Layout table for investigator information
Study Director: Pfizer CT.gov Call Center Pfizer
Principal Investigator: Sylvester Pawlak, APRN Pfizer
Additional Information:
Layout table for additonal information
Responsible Party: Pfizer
ClinicalTrials.gov Identifier: NCT04065633    
Other Study ID Numbers: B7451032
First Posted: August 22, 2019    Key Record Dates
Last Update Posted: January 7, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Pfizer:
Phase 1 Bioequivalence Study
Healthy Participants
Estimation of the Effect of Food
Relative Bioavailability
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Dermatitis
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases